PNC-27 (PNC27)
Anti-Cancer Peptide · p53-HDM-2 Disruptor
Overview
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes,…
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not…
PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
Demonstrated effectiveness against breast cancer cell lines.
Induces necrosis of K-562 leukemia cells through HDM-2 binding.
Mechanism
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes,…
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not…
PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
Research areas
- PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes,…
- PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not…
- PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
- Demonstrated effectiveness against breast cancer cell lines.
- Induces necrosis of K-562 leukemia cells through HDM-2 binding.
Research notes
- Limited data - primarily preclinical research
- Generally well-tolerated in animal studies
- Not applicable - not approved for human use
- Not approved for human use
- Experimental research peptide only
Questions
Why is PNC-27 described as 'cancer cell-selective' when normal cells can express HDM-2?
The key difference is location. Normal cells express HDM-2 intracellularly, not on their cell surface. PNC-27 requires membrane-bound HDM-2 to form pores. Cancer cells uniquely express HDM-2 on their plasma membrane, making them susceptible to attack while normal cells are completely spared. This surface expression is…
Is PNC-27 closer to clinical trials than other peptide cancer therapies?
Not yet. PNC-27 remains in preclinical research with no human clinical trials initiated as of 2025. While it's been studied since 2000, it hasn't progressed to human testing. That's partly because cancer drug development is slow and partly because peptide therapeutics face delivery challenges that are being actively…
Why would someone take PNC-27 if it doesn't prevent cancer recurrence?
PNC-27 is purely experimental—it eradicates tumor cells in mouse models through a unique mechanism (membrane pore formation + mitochondrial damage). Once human trials exist (which they don't yet), the intent would be cancer treatment, not prevention. Until then, it's a research tool for understanding cancer-selective…
Could PNC-27 work on cancers that don't express HDM-2?
No. PNC-27's entire mechanism depends on membrane HDM-2 binding. Cancers without membrane HDM-2 expression wouldn't respond. This is both a strength (high selectivity) and a limitation (requires the right cancer type). Assessing HDM-2 status would be critical before attempting any therapeutic use.